微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 61.75% | -0.9% | -0.65% | 36/159 | 49.75% | 首药控股 | 96.95% | 行业排名> |
| 2026-06-30 | 62.15% | -1.6% | 4.51% | 42/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 59.47% | 7.41% | -2.81% | 58/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 61.19% | 6.44% | -1.8% | 48/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 62.31% | 14.05% | -1.35% | 44/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 63.16% | 15.17% | 14.08% | 42/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 55.36% | 0.46% | -3.69% | 62/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 57.49% | 8.72% | 5.23% | 57/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 54.63% | 6.6% | -0.39% | 67/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 54.84% | 6.11% | -0.48% | 68/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 55.11% | 5.28% | 4.22% | 63/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 52.88% | -9.08% | 3.17% | 71/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 51.25% | -10.77% | -0.84% | 71/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 51.68% | -11.15% | -1.26% | 73/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 52.35% | -9.79% | -9.99% | 71/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 58.15% | 0.18% | 1.25% | 63/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 57.44% | -2.84% | -1.27% | 64/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 58.17% | -0.14% | 0.25% | 63/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 58.03% | 1.97% | -0.04% | 61/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 58.05% | 4.34% | -1.8% | 67/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 59.11% | 1.37% | 1.48% | 55/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 58.25% | 3.54% | 2.36% | 60/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 56.91% | 6.86% | 2.29% | 60/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 55.64% | -8.1% | -4.6% | 68/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 58.32% | -3.89% | 3.66% | 53/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 56.26% | -5.24% | 5.64% | 57/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 53.25% | -9.94% | -12.04% | 56/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 60.54% | 2.46% | -0.22% | 55/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 60.68% | 2.76% | 2.2% | 43/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 59.37% | 3.15% | 0.4% | 50/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 59.13% | 5% | 0.08% | 42/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 59.09% | 4.9% | 0.07% | 56/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 59.04% | 6.51% | 2.59% | 42/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.55% | 5.81% | 2.19% | 46/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 56.32% | 12.56% | -0.01% | 47/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 56.32% | 10.59% | 1.6% | 53/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 55.44% | 8.24% | 1.92% | 36/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 54.39% | 8.94% | 8.71% | 37/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 50.03% | 9.57% | -1.76% | 40/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 50.93% | 16.48% | -0.56% | 48/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 51.21% | 16.45% | 2.58% | 30/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 49.93% | 13.6% | 9.34% | 36/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 45.67% | 15.11% | 4.44% | 31/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |